Huss, Michael
Dirks, Bryan
Gu, Joan
Robertson, Brigitte
Newcorn, Jeffrey H.
Ramos-Quiroga, J. Antoni
Funding for this research was provided by:
Shire Development LLC
Article History
Received: 19 July 2017
Accepted: 15 January 2018
First Online: 13 February 2018
Compliance with ethical standards
:
: J Gu and B Robertson are employees of Shire and own stock or stock options. B Dirks is a former employee of Shire. The following authors have received compensation for serving as consultants or speakers for, or they or the institutions they work for have received research support or royalties from, the companies or organizations indicated: M Huss (Actelion, Eli Lilly, Engelhard Arzneimittel, Janssen-Cilag, Medice, Novartis, Shire, and Steiner Arzneimittel); J Newcorn (Akili Interactive, Alcobra, Enzymotec, Ironshore, Lundbeck, Medice, National Football League, Neos Therapeutics, NLS, Pearson, Shire, Sunovion, and Supernus); and JA Ramos-Quiroga (Ferrer, Eli Lilly, Janssen-Cilag, Novartis, Lundbeck, Shire, Rovi, and Laboratorios Rubió). Study funded by Shire Development LLC.